Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target

Alnylam Pharmaceuticals demonstrates a robust financial trajectory with projected combined net product revenues nearing $2.99 billion in 2025, which represents an impressive year-over-year growth of approximately 81%, significantly exceeding initial revenue guidance. The company has maintained healthy gross margins while simultaneously expanding operating leverage, with revenue from its Rare franchise contributing approximately $500 million, reflecting steady double-digit growth and solid performance from its key products, Givlaari and Oxlumo. Moreover, the anticipated rise in non-GAAP R&D and SG&A expenses by roughly 26% from 2025 to 2026 underlines the company's commitment to scaling its ATTR-CM programs and advancing its promising clinical pipeline, reinforcing a positive outlook for future growth.

Alnylam Pharmaceuticals faces a negative financial outlook due to expected significant declines in revenues, with guidance of $400 million to $500 million for collaboration and royalty revenues in 2026, down from approximately $727 million in 2025, largely impacted by the non-recurrence of a substantial milestone from the previous year. The company anticipates a mid-single-digit decrease in the net price of Amvuttra, alongside an estimated $25 million reduction in international revenues due to a pricing reset in Germany, contributing to overall sequential softness in revenue growth for the first quarter of 2026. Additionally, the anticipated regulatory approval risks for various clinical programs further threaten the company’s long-term financial projections, potentially leading to downward revisions in risk-adjusted forecasts.